Patent classifications
C07C227/12
Pharmaceutically Active Compounds
The invention is directed to compounds of general formula (I)
##STR00001##
and pharmaceutical compositions containing such compounds. The compounds and compositions have valuable pharmaceutical properties. In particular, they may be used for the treatment of cancer. Novel intermediates and novel methods of preparation are also disclosed.
THERMO-THICKENING COMPOUNDS FOR NON-POLAR LIQUID
A bis-urea compound of general formula (IV):
##STR00001##
The compound is useful as a thermo-thickening agent in a non-polar liquid such as engine lubricating oil or thermosetting varnish. Also, a method for preparing the thermo-thickening compound. Further, a composition comprising the thermo-thickening compound and a non-polar liquid.
THERMO-THICKENING COMPOUNDS FOR NON-POLAR LIQUID
A bis-urea compound of general formula (IV):
##STR00001##
The compound is useful as a thermo-thickening agent in a non-polar liquid such as engine lubricating oil or thermosetting varnish. Also, a method for preparing the thermo-thickening compound. Further, a composition comprising the thermo-thickening compound and a non-polar liquid.
POSITRON IMAGING TOMOGRAPHY IMAGING AGENT COMPOSITION ADN METHOD FOR BACTERIAL INFECTION
The present invention provides a composition comprising the compound having the structure:
##STR00001##
or a salt of the compound; 4-amino-2-[.sup.19F]-fluorobenzoic acid or a salt of 4-amino-2-[.sup.19F]-fluorobenzoic acid; and at least one acceptable carrier.
POSITRON IMAGING TOMOGRAPHY IMAGING AGENT COMPOSITION ADN METHOD FOR BACTERIAL INFECTION
The present invention provides a composition comprising the compound having the structure:
##STR00001##
or a salt of the compound; 4-amino-2-[.sup.19F]-fluorobenzoic acid or a salt of 4-amino-2-[.sup.19F]-fluorobenzoic acid; and at least one acceptable carrier.
Micro/nano materials, products obtained by covalently modifying surface of micro/nano materials with hydrophilic materials, and method for making same
Micro-nano materials, products obtained by covalently modifying the surfaces of micro/nano materials with hydrophilic materials, and methods for making the same. The micro/nano materials on the surfaces have carboxyl groups or/and pro-carboxyl groups which are converted into their active esters. The products are covalently modified by forming amide bonds between the active esters on the surfaces and the modification agents; where the modification agents are hydrophilic compounds and/or hydrophilic polymers bearing primary and/or secondary aliphatic amines. Monomers bearing carboxyl groups and/or pro-carboxyl groups are used to produce an adequate number of carboxyl groups and/or pro-carboxyl groups on the surface of a polymer material to be modified. The carboxyl groups and/or pro-carboxyl groups are converted into active esters. A reasonably-sized modification agent bearing primary and/or secondary amines, zwitterions and hydrophilic linear spacer arms is used to form amide bonds and obtain a covalently modified surface layer.
Micro/nano materials, products obtained by covalently modifying surface of micro/nano materials with hydrophilic materials, and method for making same
Micro-nano materials, products obtained by covalently modifying the surfaces of micro/nano materials with hydrophilic materials, and methods for making the same. The micro/nano materials on the surfaces have carboxyl groups or/and pro-carboxyl groups which are converted into their active esters. The products are covalently modified by forming amide bonds between the active esters on the surfaces and the modification agents; where the modification agents are hydrophilic compounds and/or hydrophilic polymers bearing primary and/or secondary aliphatic amines. Monomers bearing carboxyl groups and/or pro-carboxyl groups are used to produce an adequate number of carboxyl groups and/or pro-carboxyl groups on the surface of a polymer material to be modified. The carboxyl groups and/or pro-carboxyl groups are converted into active esters. A reasonably-sized modification agent bearing primary and/or secondary amines, zwitterions and hydrophilic linear spacer arms is used to form amide bonds and obtain a covalently modified surface layer.
BENZYL PHENYL ETHER DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USES THEREOF
The present invention discloses a benzyl phenyl ether derivative, a preparation method therefor, and a pharmaceutical composition and uses thereof. Specifically, the invention relates to benzyl phenyl ether derivatives represented by formula (I), a pharmaceutically-acceptable salt thereof, a stereoisomer thereof, a preparation method therefor, a pharmaceutical composition containing the one or more compounds, and uses of the compounds in treating diseases related to PD-1/PD-L1 signal channels, such as cancers, infectious diseases and autoimmune diseases.
##STR00001##
BENZYL PHENYL ETHER DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USES THEREOF
The present invention discloses a benzyl phenyl ether derivative, a preparation method therefor, and a pharmaceutical composition and uses thereof. Specifically, the invention relates to benzyl phenyl ether derivatives represented by formula (I), a pharmaceutically-acceptable salt thereof, a stereoisomer thereof, a preparation method therefor, a pharmaceutical composition containing the one or more compounds, and uses of the compounds in treating diseases related to PD-1/PD-L1 signal channels, such as cancers, infectious diseases and autoimmune diseases.
##STR00001##
PHENYLATE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USES THEREOF
The present invention discloses a phenylate derivative, a preparation method therefor, and a pharmaceutical composition and uses thereof. Specifically, the invention relates to phenylate derivatives represented by formula (I), a pharmaceutically-acceptable salt thereof, a stereoisomer thereof, a preparation method therefor, a pharmaceutical composition containing the one or more compounds, and uses of the compounds in treating diseases related to PD-1/PD-L1 signal channels, such as cancers, infectious diseases and autoimmune diseases.
##STR00001##